AbbVie (ABBV) Liabilities and Shareholders Equity (2012 - 2026)

AbbVie (ABBV) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $136.5 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $136.5 billion, changed 0.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $541.5 billion (down 2.73% YoY), and the FY2025 annual result was $134.0 billion, down 0.89% from the prior year.
• Liabilities and Shareholders Equity improved to $136.5 billion in Q1 2026 per ABBV's latest filing, from $134.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $148.9 billion in Q1 2024 and troughed at $133.9 billion in Q3 2025.
• A 5-year average of $138.5 billion and a median of $136.5 billion in 2026 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity increased 10.65% in 2024, then retreated 8.54% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $138.8 billion in 2022, then decreased by 2.95% to $134.7 billion in 2023, then climbed by 0.33% to $135.2 billion in 2024, then dropped by 0.89% to $134.0 billion in 2025, then grew by 1.87% to $136.5 billion in 2026.
• Business Quant data shows ABBV's Liabilities and Shareholders Equity at $136.5 billion in Q1 2026, $134.0 billion in Q4 2025, and $133.9 billion in Q3 2025.